Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Authors:

Top Cited Papers
Open Access
Abstract
In the trials of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program (Aug. 17 issue),1 patients who had been assigned to receive canagliflozin had significantly lower rates of the primary outcome (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) than those assigned to receive placebo (hazard ratio, 0.86; 95% confidence interval [CI], 0.75 to 0.97). Beyond statistical significance, however, a treatment difference must be clinically significant.2 On an absolute scale, these results show that more than 200 patients must receive daily canagliflozin for the duration of the trial (mean, 3.6 years; median, 2.4 years) in order for 1 patient to benefit. More importantly, the trials show a risk of amputation that is almost twice as high among patients receiving canagliflozin as among patients receiving placebo (hazard ratio, 1.97; 95% CI, 1.41 to 2.75). Although the risk was primarily at the level of the toes and metatarsals, 29% of the affected participants had a more proximal amputation. Similar to other new medications for type 2 diabetes, canagliflozin is expensive, with a suggested price per tablet of $10.53 (€9.09, £8.03).3 Economic models4,5 need to be updated to consider the benefit–harm ratio emerging from these new data.

This publication has 8 references indexed in Scilit: